Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - Time to Buy?

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report)'s stock price gapped up before the market opened on Friday . The stock had previously closed at $17.69, but opened at $18.18. Spyre Therapeutics shares last traded at $17.44, with a volume of 14,384 shares.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Wolfe Research started coverage on shares of Spyre Therapeutics in a research report on Tuesday, March 18th. They issued an "outperform" rating and a $27.00 price objective for the company. Wedbush reissued an "outperform" rating and set a $65.00 price target on shares of Spyre Therapeutics in a research report on Monday, January 13th. Finally, The Goldman Sachs Group upgraded Spyre Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 18th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $50.33.

Spyre Therapeutics Stock Down 1.1 %

The company has a market cap of $961.70 million, a P/E ratio of -2.13 and a beta of 2.98. The business has a fifty day moving average price of $20.45 and a 200-day moving average price of $25.47.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($0.89) by $0.08. As a group, research analysts expect that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current year.

Institutional Trading of Spyre Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Intech Investment Management LLC acquired a new stake in shares of Spyre Therapeutics in the third quarter valued at approximately $246,000. Charles Schwab Investment Management Inc. increased its stake in Spyre Therapeutics by 239.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 333,275 shares of the company's stock worth $9,802,000 after acquiring an additional 235,094 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Spyre Therapeutics by 15.0% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 43,460 shares of the company's stock valued at $1,278,000 after acquiring an additional 5,678 shares in the last quarter. FMR LLC lifted its position in shares of Spyre Therapeutics by 1.5% during the 3rd quarter. FMR LLC now owns 7,623,881 shares of the company's stock valued at $224,218,000 after acquiring an additional 115,898 shares during the period. Finally, MetLife Investment Management LLC grew its holdings in shares of Spyre Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 20,132 shares of the company's stock worth $592,000 after purchasing an additional 11,344 shares in the last quarter. Institutional investors and hedge funds own 80.39% of the company's stock.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).